{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T05:20:13Z","timestamp":1789968013345,"version":"4.0.1"},"reference-count":18,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,11,24]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>The combination of rituximab, lenalidomide, and ibrutinib is associated with a high incidence of rash in follicular lymphoma (all grades 82%). Efficacy of the triplet appears similar to rituximab-lenalidomide in the same patient population.<\/jats:p>","DOI":"10.1182\/blood-2016-06-718106","type":"journal-article","created":{"date-parts":[[2016,10,4]],"date-time":"2016-10-04T03:19:20Z","timestamp":1475551160000},"page":"2510-2516","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":49,"title":["Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103"],"prefix":"10.1182","volume":"128","author":[{"given":"Chaitra S.","family":"Ujjani","sequence":"first","affiliation":[{"name":"Lombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Washington, DC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sin-Ho","family":"Jung","sequence":"additional","affiliation":[{"name":"Alliance Statistics and Data Center, Duke University, Durham, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandelyn","family":"Pitcher","sequence":"additional","affiliation":[{"name":"Alliance Statistics and Data Center, Duke University, Durham, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Martin","sequence":"additional","affiliation":[{"name":"Meyer Cancer Center, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven I.","family":"Park","sequence":"additional","affiliation":[{"name":"UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristie A.","family":"Blum","sequence":"additional","affiliation":[{"name":"Division of Hematology, The Ohio State University, Columbus, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali M.","family":"Smith","sequence":"additional","affiliation":[{"name":"University of Chicago Medicine Comprehensive Cancer Center, University of Chicago, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myron","family":"Czuczman","sequence":"additional","affiliation":[{"name":"Roswell Park Cancer Institute, State University of New York at Buffalo, Buffalo, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Davids","sequence":"additional","affiliation":[{"name":"Dana-Farber\/Partners CancerCare, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellis","family":"Levine","sequence":"additional","affiliation":[{"name":"Roswell Park Cancer Institute, State University of New York at Buffalo, Buffalo, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel D.","family":"Lewis","sequence":"additional","affiliation":[{"name":"Norris Cotton Cancer Center, The Geisel School of Medicine at Dartmouth, Lebanon, NH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott E.","family":"Smith","sequence":"additional","affiliation":[{"name":"Cardinal Bernardin Cancer Center, Loyola University Medical Center, Maywood, IL; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy L.","family":"Bartlett","sequence":"additional","affiliation":[{"name":"Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Leonard","sequence":"additional","affiliation":[{"name":"Meyer Cancer Center, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce D.","family":"Cheson","sequence":"additional","affiliation":[{"name":"Lombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Washington, DC;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"9873","key":"2019111902330848200_B1","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"19","key":"2019111902330848200_B2","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"issue":"12","key":"2019111902330848200_B3","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1200\/JCO.2012.45.0866","article-title":"R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 Trial conducted by the Fondazione Italiana Linfomi","volume":"31","author":"Federico","year":"2013","journal-title":"J Clin Oncol"},{"issue":"9759","key":"2019111902330848200_B4","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"issue":"31","key":"2019111902330848200_B5","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1200\/JCO.2014.59.9258","article-title":"Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance)","volume":"33","author":"Leonard","year":"2015","journal-title":"J Clin Oncol"},{"issue":"15","key":"2019111902330848200_B6","article-title":"CALGB 50803 (Alliance): A phase II trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma [abstract]","volume":"32","author":"Martin","year":"2014","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111902330848200_B7","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S1470-2045(14)70455-3","article-title":"Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial","volume":"15","author":"Fowler","year":"2014","journal-title":"Lancet Oncol"},{"issue":"21","key":"2019111902330848200_B8","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.156.156","article-title":"The Bruton\u2019s tyrosine kinase inhibitor ibrutinib (PCI-32765) is active and tolerated in relapsed follicular lymphoma [abstract]","volume":"120","author":"Fowler","year":"2012","journal-title":"Blood"},{"issue":"23","key":"2019111902330848200_B9","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.2706.2706","article-title":"Long-term follow-up and analysis of dose groups with ibrutinib in relapsed follicular lymphoma [abstract]","volume":"126","author":"Fowler","year":"2015","journal-title":"Blood"},{"issue":"21","key":"2019111902330848200_B10","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.800.800","article-title":"Ibrutinib monotherapy in relapsed\/refractory follicular lymphoma: preliminary results of a phase 2 consortium trial [abstract]","volume":"124","author":"Bartlett","year":"2014","journal-title":"Blood"},{"issue":"5","key":"2019111902330848200_B11","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"20","key":"2019111902330848200_B12","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.4155\/bio.15.159","article-title":"Bioanalysis of ibrutinib and its active metabolite in human plasma: selectivity issue, impact assessment and resolution","volume":"7","author":"de Vries","year":"2015","journal-title":"Bioanalysis"},{"issue":"282","key":"2019111902330848200_B13","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Statist Assoc"},{"issue":"1","key":"2019111902330848200_B14","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J Clin Oncol"},{"key":"2019111902330848200_B15","unstructured":"Ibrutinib prescribing information packet. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/205552Orig1s012lbl.pdf. Accessed 28 June 2016."},{"issue":"23","key":"2019111902330848200_B16","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.470.470","article-title":"Ibrutinib plus rituximab in treatment-naive patients with follicular lymphoma: results from a multicenter, phase 2 study [abstract]","volume":"126","author":"Fowler","year":"2015","journal-title":"Blood"},{"issue":"23","key":"2019111902330848200_B17","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.3983.3983","article-title":"Updated results of a phase I study of ibrutinib and lenalidomide in patients with relapsed and refractory B-cell non-Hodgkin\u2019s lymphoma [abstract]","volume":"126","author":"Christian","year":"2015","journal-title":"Blood"},{"issue":"21","key":"2019111902330848200_B18","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.3091.3091","article-title":"Unexpected and serious toxicity observed with combined idelalisib, lenalidomide and rituximab in relapsed\/refractory B cell lymphomas: Alliance A051201 and A051202 [abstract]","volume":"124","author":"Smith","year":"2014","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/21\/2510\/1397043\/blood718106.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/21\/2510\/1397043\/blood718106.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T07:35:45Z","timestamp":1574148945000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/128\/21\/2510\/35716\/Phase-1-trial-of-rituximab-lenalidomide-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,24]]},"references-count":18,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2016,11,24]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-06-718106","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,24]]}}}